Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

61. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis 27338778 2016 06 24 2017 04 10 1468-2060 76 2 2017 Feb Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. 414-417 10.1136/annrheumdis-2016-209322 Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over (...) 10 years and has a well-established safety profile across multiple indications. To update adverse events (AEs) of special interest from global adalimumab clinical trials in patients with RA. This analysis includes 15 132 patients exposed to adalimumab in global RA clinical trials. AEs of interest included overall infections, laboratory abnormalities and AEs associated with influenza vaccination. Pregnancy outcome data were collected from the Adalimumab Pregnancy Registry. Serious infections

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

62. Adalimumab for treating moderate to severe hidradenitis suppurativa

Adalimumab for treating moderate to severe hidradenitis suppurativa Adalimumab for treating moder Adalimumab for treating moderate to ate to se sev vere hidr ere hidradenitis suppur adenitis suppurativa ativa T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 43Contents Contents 1 Recommendations 4 2 The technology 5

National Institute for Health and Clinical Excellence - Technology Appraisals2016

63. Adalimumab (Humira) - Treatment of moderate to severe chronic plaque psoriasis

Adalimumab (Humira) - Treatment of moderate to severe chronic plaque psoriasis Published 11 July 2016 Statement of Advice: adalimumab (Humira ® ) Pre-filled Pen, Pre-filled Syringe and Vial (No: 1173/16) AbbVie Limited 10 June 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation adalimumab (Humira ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of moderate to severe chronic plaque psoriasis in adult patients who (...) are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08). SMC has previously accepted adalimumab for restricted use for the treatment of chronic plaque psoriasis in adult patients who failed to respond to or have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA. It is restricted to patients with severe disease as defined by a total Psoriasis Area Severity Index score of =10 and a Dermatology Life Quality

Scottish Medicines Consortium2016

64. Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants

Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants'', 1 July 2016 {1} {1} {1} | | > > > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable. Full text

Prescrire2016

65. Adalimumab (Humira) for uveitis in paediatric patients - second line

Adalimumab (Humira) for uveitis in paediatric patients - second line Adalimumab (Humira) for uveitis in paediatric patients – second line Adalimumab (Humira) for uveitis in paediatric patients – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Adalimumab (Humira) for uveitis in paediatric patients – second line. Birmingham: NIHR (...) Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Uveitis affects the lining of the eye. It is an inflammation that can lead to eye pain, eye redness, headaches, and visual problems that can become permanent. In many cases the cause of uveitis is unknown, but it is much more common in patients who are affected by a form of childhood arthritis called juvenile idiopathic arthritis (JIA). Adalimumab is a drug that is already used to treat JIA

Health Technology Assessment (HTA) Database.2016

66. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try

NIHR HTA programme2016

67. Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Scottish Medicines Consortium2016

68. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2016

69. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404

NIHR HTA programme2016

70. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Abatacept, adalimumab, etanercept and Abatacept, adalimumab, etanercept and tocilizumab for treating juv tocilizumab for treating juvenile enile idiopathic arthritis idiopathic arthritis T echnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Technology Appraisals2016

71. Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study) 27747511 2018 11 13 2198-6576 3 1 2016 Jun Rheumatology and therapy Rheumatol Ther Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). 129-141 10.1007/s40744-015-0023-x There is insufficient evidence regarding the appropriate dose (...) of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose (>0-<4

Rheumatology and therapy2015 Full Text: Link to full Text with Trip Pro

72. Adalimumab (Humira) - for the treatment of severe chronic plaque psoriasis in children and adolescents

Adalimumab (Humira) - for the treatment of severe chronic plaque psoriasis in children and adolescents %PDF-1.5 %���� 36 0 obj > endobj 51 0 obj >/Filter/FlateDecode/ID[ ]/Index[36 24]/Info 35 0 R/Length 78/Prev 98256/Root 37 0 R/Size 60/Type/XRef/W[1 2 1]>>stream h�bbd``b`j�S@D�`�A�g�Dh��s �'�x��$�"Aڔ���� L� ��,F���]� �i endstream endobj startxref 0 %%EOF 59 0 obj >stream h�b``�e``*e```�pa@�@���р,� � �J � � } �dxnpH0G0^gx�`٨��������,�IL��f�00ֵAD� ŧ 2 endstream endobj 37 0 obj >/Metadata 2 0

All Wales Medicines Strategy Group2015

73. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis 26223543 2015 10 28 2016 02 10 2017 02 20 2151-4658 67 11 2015 Nov Arthritis care & research Arthritis Care Res (Hoboken) A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. 1503-12 10.1002/acr.22657 Enthesitis-related arthritis (ERA) is a juvenile idiopathic arthritis (JIA (...) ) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA. This is a phase III, multicenter, randomized double-blind study in patients ages ≥6 to <18 years with ERA treated with adalimumab (24 mg/m(2) , maximum dose 40 mg every other week) or placebo for 12 weeks, followed by up to 192 weeks of open-label adalimumab. The primary end point was percent change from baseline in number of active

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

74. Adalimumab (Humira)

Adalimumab (Humira) Adalimumab | CADTH.ca Find the information you need Adalimumab Adalimumab Last Updated: Result type: Reports Project Number: SR0455-000 Product Line: Generic Name: Adalimumab Brand Name: Humira Manufacturer: AbbVie Corporation Indications: Hidradenitis suppurativa Submission Type: New Indication Project Status: Active Date Recommendation Issued: May 19, 2016 Recommendation Type: Reimburse with clinical criteria and/or conditions Tags hidradenitis suppurativa, dermatology

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

75. Adalimumab (Humira) - Treatment of severe chronic plaque psoriasis in children and adolescents

Adalimumab (Humira) - Treatment of severe chronic plaque psoriasis in children and adolescents Published 13 July 2015 Product Update: adalimumab (Humira ® ) 40 mg/0.8 ml solution injection (Humira ® ) SMC No. (1068/15) AbbVie Ltd 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission adalimumab (Humira ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. SMC restriction: Patients with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of =10 and a Dermatology Life Quality Index (DLQI) of >10. Treatment

Scottish Medicines Consortium2015

76. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2562. 2015 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans Language Published

Health Technology Assessment (HTA) Database.2015

77. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. 26154787 2015 07 09 2015 07 16 2015 11 19 1533-4406 373 2 2015 Jul 09 The New England journal of medicine N. Engl. J. Med. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. 136-44 10.1056/NEJMoa1501646 Little is known about the effect of specific anti-interleukin-23 therapy, as compared with established anti-tumor necrosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis. In a 52 (...) -week, phase 2, dose-ranging, randomized, double-blind, placebo-controlled, active-comparator trial, we compared guselkumab (CNTO 1959), an anti-interleukin-23 monoclonal antibody, with adalimumab in patients with moderate-to-severe plaque psoriasis. A total of 293 patients were randomly assigned to receive guselkumab (5 mg at weeks 0 and 4 and every 12 weeks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0 and 4 and every 12 weeks thereafter, 100 mg every 8 weeks, or 200 mg at weeks 0 and 4

NEJM2015

78. Adalimumab (Humira) - Treatment of severe chronic plaque psoriasis in children and adolescents

Adalimumab (Humira) - Treatment of severe chronic plaque psoriasis in children and adolescents Published 13 July 2015 Product Update: adalimumab (Humira ® ) 40 mg/0.8 ml solution injection (Humira ® ) SMC No. (1068/15) AbbVie Ltd 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission adalimumab (Humira ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. SMC restriction: Patients with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of =10 and a Dermatology Life Quality Index (DLQI) of >10. Treatment

Scottish Medicines Consortium2015

79. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) 25926155 2016 04 09 2016 08 29 2016 04 09 1468-2060 75 5 2016 May Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). 855-61 10.1136/annrheumdis-annrheumdis-2014-206747 Published evidence on the long-term safety of etanercept (ETA) and adalimumab (ADA (...) . Minden Kirsten K German Rheumatism Research Centre Berlin, a Leibniz Institute, Berlin, Germany Charité Universitätsmedizin Berlin, Children's university hospital, Berlin, Germany. eng Journal Article Observational Study Research Support, Non-U.S. Gov't 2015 04 29 England Ann Rheum Dis 0372355 0003-4967 0 Antirheumatic Agents 0 Biological Products 0 Tumor Necrosis Factor-alpha FYS6T7F842 Adalimumab OP401G7OJC Etanercept YL5FZ2Y5U1 Methotrexate IM Adalimumab adverse effects therapeutic use Adolescent

EvidenceUpdates2015

80. Adalimumab (Humira) - for the treatment of active enthesitis-related arthritis

Adalimumab (Humira) - for the treatment of active enthesitis-related arthritis AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 1015 – April 2015 Adalimumab (Humira ® ) 40 mg solution for injection in pre-filled syringe and pre-filled pen, 40 mg/0.8 ml solution for injection single use (...) (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Adalimumab (Humira ® ) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant

All Wales Medicines Strategy Group2015